Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IRMD 
Iradimed Co (IRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: IRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $75
1 Year Target Price $75
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.23% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 934.03M USD | Price to earnings Ratio 45.61 | 1Y Target Price 75 |
Price to earnings Ratio 45.61 | 1Y Target Price 75 | ||
Volume (30-day avg) 2 | Beta 1.03 | 52 Weeks Range 46.33 - 78.38 | Updated Date 10/18/2025 |
52 Weeks Range 46.33 - 78.38 | Updated Date 10/18/2025 | ||
Dividends yield (FY) 0.87% | Basic EPS (TTM) 1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 26.61% | Operating Margin (TTM) 33.26% |
Management Effectiveness
Return on Assets (TTM) 15.15% | Return on Equity (TTM) 23.75% |
Valuation
Trailing PE 45.61 | Forward PE 35.59 | Enterprise Value 851141961 | Price to Sales(TTM) 12.03 |
Enterprise Value 851141961 | Price to Sales(TTM) 12.03 | ||
Enterprise Value to Revenue 10.96 | Enterprise Value to EBITDA 34.6 | Shares Outstanding 12720002 | Shares Floating 7194815 |
Shares Outstanding 12720002 | Shares Floating 7194815 | ||
Percent Insiders 36.82 | Percent Institutions 58.47 |
Upturn AI SWOT
Iradimed Co
Company Overview
History and Background
Iradimed Co. was founded in 1992. It focuses on developing innovative magnetic resonance imaging (MRI) compatible products. It initially specialized in medical device design and manufacturing before concentrating on MRI-compatible solutions.
Core Business Areas
- MRI Compatible IV Infusion Pump Systems: Iradimed designs, manufactures, and distributes MRI-compatible IV infusion pump systems, including the MRidium MRI IV Infusion Pump system, which is designed for use in MRI environments.
- MRI Compatible Patient Monitoring Systems: The company also offers MRI-compatible patient vital signs monitoring systems, such as the 3880 MRI Patient Vital Signs Monitoring System, which monitors various physiological parameters during MRI procedures.
Leadership and Structure
John P. Sperzel III is the Chairman, President, and Chief Executive Officer. The company maintains a relatively lean organizational structure focused on engineering, manufacturing, and sales/marketing of its specialized product lines.
Top Products and Market Share
Key Offerings
- MRidium MRI IV Infusion Pump System: The MRidium MRI IV Infusion Pump System is a key product designed for precise fluid delivery in MRI environments. While exact market share data is difficult to obtain, Iradimed is considered a leading player in this niche market. Competitors include smaller specialized firms.
- 3880 MRI Patient Vital Signs Monitoring System: The 3880 MRI Patient Vital Signs Monitoring System provides real-time monitoring of vital signs during MRI procedures. As above, exact market share data is not readily available, but Iradimed holds a significant position in this market segment. Competitors include Siemens Healthineers (SIEGY) and Philips (PHG) in terms of overall patient monitoring.
Market Dynamics
Industry Overview
The MRI-compatible device market is a niche within the broader medical device industry, driven by the increasing use of MRI technology in diagnostics and treatment. It's characterized by high regulatory hurdles and specialized engineering requirements.
Positioning
Iradimed is positioned as a leader in MRI-compatible infusion and monitoring systems, focusing on safety and reliability in MRI environments. Their competitive advantage lies in their deep expertise and specialized product portfolio.
Total Addressable Market (TAM)
The TAM for MRI-compatible devices is estimated to be in the hundreds of millions of dollars annually. Iradimed is well-positioned to capture a significant portion of this TAM due to its focused product line and strong reputation.
Upturn SWOT Analysis
Strengths
- Specialized expertise in MRI-compatible devices
- Strong brand reputation in a niche market
- Proprietary technology and patents
- FDA approval and regulatory compliance
Weaknesses
- Limited product diversification
- Reliance on a single market segment (MRI)
- Smaller scale compared to larger medical device companies
- High customer concentration
Opportunities
- Expanding product line within the MRI environment
- Geographic expansion into international markets
- Developing new MRI-compatible technologies
- Partnerships with MRI equipment manufacturers
Threats
- Competition from larger medical device companies
- Technological obsolescence
- Changes in MRI technology and adoption rates
- Regulatory changes affecting MRI devices
Competitors and Market Share
Key Competitors
- PHG
- SIEGY
- MDSO
Competitive Landscape
Iradimed possesses specialized advantages in MRI compatibility, but it is significantly smaller than competitors like Philips and Siemens, which have broader product portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be assessed based on past revenue and earnings data.
Future Projections: Analyst estimates for future revenue and earnings growth would be included.
Recent Initiatives: Recent initiatives include product innovation and expansion into new markets.
Summary
Iradimed is a strong niche player in the MRI-compatible device market, with a leading position in infusion and monitoring systems. Its specialized expertise and strong brand reputation provide competitive advantages. However, its limited product diversification and smaller scale compared to larger competitors pose potential risks. Continued innovation and market expansion are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Market research reports, Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iradimed Co
Exchange NASDAQ | Headquaters Winter Springs, FL, United States | ||
IPO Launch date 2014-07-16 | Founder, Chairman, CEO & President Mr. Roger E. Susi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 160 | Website https://www.iradimed.com |
Full time employees 160 | Website https://www.iradimed.com | ||
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. The company was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.